Involvement of a dysfunctional dopamine-D1/N-methyl-D-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine

Molecular Pharmacology

Volumn 71, Issue 6, 2007, Pages 1598-1609

  Mouri, Akihiro ^a   Noda, Yukihiro ^a,b   Noda, Akihiro ^a   Nakamura, Tomonobu ^a   Tokura, Takanobu ^a   Yura, Yoshimitsu ^a   Nitta, Atsumi ^a   Furukawa, Hiroshi ^b   Nabeshima, Toshitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b MEIJO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 1 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; PHENCYCLIDINE; PROTEIN KINASE (CALCIUM,CALMODULIN) II;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DRUG INFUSION; DRUG WITHDRAWAL; ENZYME ACTIVATION; LEARNING DISORDER; MALE; MAZE TEST; NERVE CELL EXCITABILITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR INTRINSIC ACTIVITY; SCHIZOPHRENIA; TASK PERFORMANCE;

ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DOPAMINE AGONISTS; ENZYME ACTIVATION; GENE EXPRESSION; GLYCINE; HUMANS; LEARNING; MALE; MICE; MICROINJECTIONS; OLIGONUCLEOTIDES, ANTISENSE; PHENCYCLIDINE; PHOSPHORYLATION; PREFRONTAL CORTEX; RECEPTORS, DOPAMINE D1; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 34347350265     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.032961     Document Type: Article

References (41)

1. Ballard TM, Pauly-Evers M, Higgins GA, Ouagazzal AM, Mutel V, Borroni E, Kemp JA, Bluethmann H, and Kew JN (2002) Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 22:6713-6723.
2. 2+//calmodulin-dependent protein kinase II-dependent modifications in alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor properties. Neuroscience 136:397-403.
3. Cammarota M, Bevilaqua LR, Viola H, Kerr DS, Reichmann B, Teixeira V, Bulla M, Izquierdo I, and Medina JH (2002) Participation of CaMKII in neuronal plasticity and memory formation. Cell Mol Neurobiol 22:259-267.
4. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, and Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41:237-260.
5. Coyle JT, and Tsai G (2004) The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174:32-38.
6. Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, and Haroutunian V (2001) N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158:1400-1410.
7. Emamian ES, Karayiorgou M, and Gogos JA (2004) Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with schizophrenia. J Neurosci 24:1561-1564.
8. Enomoto T, Noda Y, Mouri A, Shin EJ, Wang D, Murai R, Hotta K, Furukawa H, Nitta A, Kim HC, et al. (2005) Long-lasting impairment of associative learning is correlated with a dysfunction of N-methyl-D- aspartate-extracellular signaling-regulated kinase signaling in mice after withdrawal from repeated administration of phencyclidine. Mol Pharmacol 68:1765-1774.
9. Exner C, Boucsein K, Degner D, and Irle E (2006) State-dependent implicit learning deficit in schizophrenia: Evidence from 20-month follow-up. Psychiatry Res 142:39-52.
10. Giese KP, Fedorov NB, Filipkowski RK, and Silva AJ (1998) Autophosphorylation at Thr286 of the alpha calcium-calmodulin kinase II in LTP and learning. Science (Wash DC) 279:870-873.
11. Ichihara K, Nabeshima T, and Kameyama T (1993) Dopaminergic agonists impair latent learning in mice: possible modulation by noradrenergic function. J Pharmacol Exp Ther 264:122-128.
12. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
13. Itokawa M, Yamada K, Yoshitsugu K, Toyota T, Suga T, Ohba H, Watanabe A, Hattori E, Shimizu H, Kumakura T, et al. (2003) A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 13:271-278.
14. Javitt DC, and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
15. Jentsch JD, Redmond DE Jr., Elsworth JD, Taylor JR, Youngren KD, and Roth RH (1997a) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science (Wash DC) 277:953-955.
16. Jentsch JD, and Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201-225.
17. Jentsch JD, Tran A, Le D, Youngren KD, and Roth RH (1997b) Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17:92-99.
18. Jiang Y and Leung AW (2005) Implicit learning of ignored visual context. Psychon Bull Rev 12:100-106.
19. Johnson JW and Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (Lond) 325:529-531.
20. Lewis DA and Lieberman JA (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28:325-334.
21. Maddox VH, Godefroi EF, and Parcell RF (1965) The synthesis of phencyclidine and other 1-arylcyclohexylamines. J Med Chem 56:230-235.
22. Mohn AR, Gainetdinov RR, Caron MG, and Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436.
23. Nabeshima T, Fukaya H, Yamaguchi K, Ishikawa K, Furukawa H, and Kameyama T (1987) Development of tolerance and supersensitivity to phencyclidine in rats after repeated administration of phencyclidine. Eur J Pharmacol 135:23-33.
24. Nabeshima T, and Ichihara K (1993) Measurement of dissociation of amnesic and behavioral effects of drug in mice. In Conn PM. (eds), Paradigms for the Study of Behavior, Methods in Neurosciences, vol 14. San Diego, Academic Press, pp 217-229.
25. Nabeshima T, Ishikawa K, Yamaguchi K, Furukawa H, and Kameyama T (1986) Methysergide-induced precipitated withdrawal syndrome in phencyclidine-dependent rats. Neurosci Lett 69:275-278.
26. Noda A, Noda Y, Kamei H, Ichihara K, Mamiya T, Nagai T, Sugiura S, Furukawa H, and Nabeshima T (2001) Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors. Neuropsychopharmacology 24:451-460.
27. Nuechterlein KH and Dawson ME (1984) Information processing and attention functioning in the developmental course of schizophrenic disorders. Schizophr Bull 10:160-203.
28. Paxinos G and Franklin KB (2004) The Mouse Brain in Stereotaxic Coordinates, compact 2nd ed., Elsevier Academic Press, San Diego.
29. Rainey JM Jr and Crowder MK (1975) Prolonged psychosis attributed to phencyclidine: report of three cases. Am J Psychiatry 132:1076-1078.
30. Rice SR, Niu N, Berman DB, Heston LL, and Sobell JL (2001) Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patients. Mol Psychiatry 6:274-284.
31. 2+/calmodulin-dependent protein kinase II at lateral amygdala synapses. J Neurosci 24:3281-3288.
32. Scott DB, Blanpied TA, and Ehlers MD (2003) Coordinated PKA and PKC phosphorylation suppresses RXR-mediated ER retention and regulates the surface delivery of NMDA receptors. Neuropharmacology 45:755-767.
33. r 32 kDa)/protein phosphatase-1 pathway regulates dephosphorylation of the NMDA receptor. J Neurosci 18:10297-10303.
34. Tingley WG, Ehlers MD, Kameyama K, Doherty C, Ptak JB, Riley CT, and Huganir RL (1997) Characterization of protein kinase A and protein kinase C phosphorylation of the N-methyl-D-aspartate receptor NR1 subunit using phosphorylation site-specific antibodies. J Biol Chem 272:5157-5166.
35. Tseng KY, and O'Donnell P (2004) Dopamine-glutamate interactions controlling prefrontal cortical pyramidal cell excitability involve multiple signaling mechanisms. J Neurosci 24:5131-5139.
36. Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H, Inturrisi CE, and Reis DJ (1993) Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature (Lond) 363:260-263.
37. Wang J, and O'Donnell P (2001) D1 dopamine receptors potentiate NMDA-mediated excitability increase in layer V prefrontal cortical pyramidal neurons. Cereb Cortex 11:452-462.
38. Wang XJ (1999) Synaptic basis of cortical persistent activity: the importance of NMDA receptors to working memory. J Neurosci 19:9587-9603.
39. Winterer G, and Weinberger DR (2004) Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci 27:683-690.
40. Xia Z, and Storm DR (2005) The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci 6:267-276.
41. Zarrindast MR, Noorbakhshnia M, Motamedi F, Haeri-Rohani A, and Rezayof A (2006) Effect of the GABAergic system on memory formation and state-dependent learning induced by morphine in rats. Pharmacology 76:93-100.